表紙
市場調查報告書

全球生技藥品市場:各產品類型、用途類型、產品平台、終端用戶、地區、各國(2020年版) - 市場洞察,競爭,及預測(2020年∼2025年)

Global Biologics Market: Analysis By Product Type, Application Type, Product Pipeline, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)

出版商 Azoth Analytics 商品編碼 926873
出版日期 內容資訊 英文 234 Pages
訂單完成後即時交付
價格
全球生技藥品市場:各產品類型、用途類型、產品平台、終端用戶、地區、各國(2020年版) - 市場洞察,競爭,及預測(2020年∼2025年) Global Biologics Market: Analysis By Product Type, Application Type, Product Pipeline, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)
出版日期: 2020年02月28日內容資訊: 英文 234 Pages
簡介

全球生技藥品市場在2019年估算為2,816億9,000萬美金。開發中產品的成長,慢性疾病的擴大,低成本的生技藥品,對醫療服務的需求劇增等,是加速該市場成長的要素。全球主要製藥會公司,為了提供滿足被認為是無法治療的各種慢性病的生產性、效率性、廉價的醫藥品的需求的生技藥品進行著獨自的努力。還有生技藥品的有效性和安全性,是在預測期間內促進市場銷售額,備受期待的重要要素之一。

本報告提供全球生技藥品市場的相關調查,市場趨勢,成長及阻礙因素,各產品類型、用途、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查方法與摘要整理

  • 調查方法
  • 摘要整理

第2章 策略性建議

  • 下一代用於生物製劑的生物科技研究開發的投資
  • 改善合理的價格和獲取的需求

第3章 產品預測

第4章 市場規模及預測

  • 市場規模,價值:2015∼2025年

第5章 市場分析:各產品類型

  • 競爭方案
  • 疫苗
  • 單株抗體
  • 重組荷爾蒙、蛋白質
  • 細胞、基因庫
  • 其他

第6章 市場分析:各用途

  • 競爭方案
  • 癌症
  • 稀少疾病及自體免疫疾病
  • 感染疾病
  • 其他

第7章 市場分析:各終端用戶

  • 競爭方案
  • 醫院
  • 診所
  • 診斷中心
  • 其他

第8章 全球性生技藥品的市場:地區分析

  • 競爭方案

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 市場動態

  • 成長要素
  • 阻礙因素
  • 市場趨勢

第13章 市場魅力

  • 各產品類型
  • 各用途
  • 各終端用戶
  • 各地區

第14章 SWOT分析

第15章 開發中產品的開發

第16章 競爭情形

  • 市場佔有率分析

第17章 企業簡介(營業內容,財務分析,事業策略)

  • Eli Lilly and Company
  • Sanofi SA
  • Pfizer
  • Roche Holding AG
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co.
  • Novo Nordisk
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
目錄

Executive Summary

Global Biologics Market was valued at USD 281.69 billion in the year 2019. Growing development of pipeline products and rapid economic growth with rising prevalence of chronic diseases and surging demand for low cost biologics and medical services, will be accelerating the biologics market growth. All prominent pharmaceutical companies around the world are making their own efforts to deliver biologics which could meet the demand of productive, efficient and inexpensive medicine for various chronic untreatable diseases. Furthermore, efficacy and safety of biologics medicine, in addition to having a capacity to treat previously grave diseases, is one of the key driving factor which has anticipated to propel the market value in forecast period.

Under the product type segment, Monoclonal Antibodies followed by Recombinant Hormones and Proteins will be attaining sustainable market growth owing to wide availability and development of medicines and technology that helps in biologics supported by availability of proficient and cost-effective manufacturing process that will be facilitating the market growth during the forecasting period.

Cancer and Hospitals secured considerable market growth under their respective segments, owing to escalating investment by hospitals in providing treatment for some long-term medical conditions, including rheumatoid arthritis, Crohn's disease, psoriasis and ankylosing spondylitis and ever growing number of patients who are suffering from cancer.

Among the regions, North America attained sustainable market growth followed by Europe and Asia Pacific. Rising prevalence of chronic diseases such as cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, obesity, and oral diseases in North America clubbed with growing investment by various global manufacturers in North America in order to attract the market growth, has been forecasted to boost the biologics market growth during the forecast period of 2020-2025.

Scope of the Report

  • The report analyses biologics market at global, regional and country-levels.
  • The report analyses Biologics Market by Product Type (Vaccines, Monoclonal Antibodies, Recombinant Hormones/Proteins, Cellular & Gene based, Others).
  • The report assesses the Biologics market By Application (Cancer, Rare and Auto-immune Diseases, Infectious Diseases, Others).
  • The report further estimate the Biologics market By End User (Hospitals, Clinics, Diagnostic Centers, Others).
  • The Global Biologics Market has been analysed By Region (North America, Europe, Asia Pacific) and By Country (United States, Canada, Germany, France, UK, Italy, China, Japan, India, South Korea).
  • The report assesses the major pipeline products in biologics. Also, the attractiveness of the market has been presented by Region, Product Type, Application and End User. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Eli Lily and Company, Sanofi SA, Pfizer, Roche Holding AG, AbbVie Inc, Amgen Inc, Merck & Co, Novo Nordisk, Bristol-Myers Squibb Company, and Johnson & Johnson.
  • The report presents the analysis of Biologics market for the historical period of 2015-2019 and the forecast period of 2020-2025.

Key Target Audience

  • Biologics companies
  • Pharmaceutical companies
  • Consulting and Advisory Firms
  • Investment Banks and Equity Firms
  • Government agenices

Table of Contents

1. Research Methodology and Executive Summary

  • 1.1 Research Methodology
  • 1.2 Executive Summary

2. Strategic Recommendations

  • 2.1 Focus on Investing in Biotech Research & Development for Next Generation Biologics
  • 2.2 Focus on Demand for Affordability and Improved Access

3. Biologics Market : Product Outlook

4. Global Biologics Market: Sizing and Forecast

  • 4.1 Market Size, By Value, Year 2015-2025

5. Global Biologics Market Segmentation - By Product Type, By Application, By End User

  • 5.1 Competitive Scenario of Global Biologics: By Product Type
  • 5.2 Vaccine - Market Size and Forecast (2015-2025)
  • 5.3 Monoclonal Antibodies - Market Size and Forecast (2015-2025)
  • 5.4 Recombinant Hormones and Proteins - Market Size and Forecast (2015-2025)
  • 5.5 Cellular and Gene Based - Market Size and Forecast (2015-2025)
  • 5.6 Others - Market Size and Forecast (2015-2025)

6. Global Biologics Market Segmentation - By Application

  • 6.1 Competitive Scenario of Global Biologics: By Application
  • 6.2 Cancer - Market Size and Forecast (2015-2025)
  • 6.3 Rare and Autoimmune Disease - Market Size and Forecast (2015-2025)
  • 6.4 Infectious Diseases - Market Size and Forecast (2015-2025)
  • 6.5 Others - Market Size and Forecast (2015-2025)

7. Global Biologics Market Segmentation - By End User

  • 7.1 Competitive Scenario of Global Biologics: By End User
  • 7.2 Hospitals - Market Size and Forecast (2015-2025)
  • 7.3 Clinics - Market Size and Forecast (2015-2025)
  • 7.4 Diagnostic Centers - Market Size and Forecast (2015-2025)
  • 7.5 Others - Market Size and Forecast (2015-2025)

8. Global Biologics Market: Regional Analysis

  • 8.1 Competitive Scenario of Global Biologics: By Region

9. North America Biologics Market: Segmentation By Product Type, By Application, By End User (2015-2025)

  • 9.1 North America Biologics Market: Size and Forecast (2015-2025), By Value
  • 9.2 North America Biologics Market - Prominent Companies
  • 9.3 Market Segmentation By Product Type (Vaccine, Monoclonal Ab, Recombinant Hormones and Proteins, Cellular and Gene Based, Others)
  • 9.4 Market Segmentation By Application (Cancer, Rare and Autoimmune Disease, Infectious Disease, Others)
  • 9.5 Market Segmentation By End User (Hospital, Clinics, Diagnostic Centers, Others)
  • 9.6 North America Biologics Market: Country Analysis
  • 9.7 Market Opportunity Chart of North America Biologics Market - By Country, By Value, 2025
  • 9.8 Competitive Scenario of North America Biologics: By Country
  • 9.9 United States Biologics Market: Size and Forecast (2015-2025), By Value
  • 9.10 United States Biologics Market Segmentation - By Product Type, By Application, By End User
  • 9.11 Canada Biologics Market: Size and Forecast (2015-2025), By Value
  • 9.12 Canada Biologics Market Segmentation - By Product Type, By Application, By End User

10. Europe Biologics Market: Segmentation By Product Type, By Application, By End User (2015-2025)

  • 10.1 Europe Biologics Market: Size and Forecast (2015-2025), By Value
  • 10.2 Europe Biologics Market - Prominent Companies
  • 10.3 Market Segmentation By Product Type (Vaccine, Monoclonal Ab, Recombinant Hormones and Proteins, Cellular and Gene Based, Others)
  • 10.4 Market Segmentation By Application (Cancer, Rare and Autoimmune Disease, Infectious Disease, Others)
  • 10.5 Market Segmentation By End User (Hospital, Clinics, Diagnostic Centers, Others)
  • 10.6 Europe Biologics Market: Country Analysis
  • 10.7 Market Opportunity Chart of Europe Biologics Market - By Country, By Value, 2025
  • 10.8 Competitive Scenario of North America Biologics: By Country
  • 10.9 Germany Biologics Market: Size and Forecast (2015-2025), By Value
  • 10.10 Germany Biologics Market Segmentation - By Product Type, By Application, By End User
  • 10.11 France Biologics Market: Size and Forecast (2015-2025), By Value
  • 10.12 France Biologics Market Segmentation - By Product Type, By Application, By End User
  • 10.13 United Kingdom Biologics Market: Size and Forecast (2015-2025), By Value
  • 10.14 United Kingdom Market Segmentation - By Product Type, By Application, By End User
  • 10.15 Italy Biologics Market: Size and Forecast (2015-2025), By Value
  • 10.16 Italy Biologics Market Segmentation - By Product Type, By Application, By End User

11. Asia Pacific Biologics Market: Segmentation By Product Type, By Application, By End User (2015-2025)

  • 11.1 Asia Pacific Biologics Market: Size and Forecast (2015-2025), By Value
  • 11.2 Asia Pacific Biologics Market - Prominent Companies
  • 11.3 Market Segmentation By Product Type (Vaccine, Monoclonal Ab, Recombinant Hormones and Proteins, Cellular and Gene Based, Others)
  • 11.4 Market Segmentation By Application (Cancer, Rare and Autoimmune Disease, Infectious Disease, Others)
  • 11.5 Market Segmentation By End User (Hospital, Clinics, Diagnostic Centers, Others)
  • 11.6 Asia Pacific Biologics Market: Country Analysis
  • 11.7 Market Opportunity Chart of Asia Pacific Biologics Market - By Country, By Value, 2025
  • 11.8 Competitive Scenario of Asia Pacific Biologics: By Country
  • 11.9 China Biologics Market: Size and Forecast (2015-2025), By Value
  • 11.10 China Biologics Market Segmentation - By Product Type, By Application, By End User
  • 11.11 Japan Biologics Market: Size and Forecast (2015-2025), By Value
  • 11.12 Japan Biologics Market Segmentation - By Product Type, By Application, By End User
  • 11.13 India Biologics Market: Size and Forecast (2015-2025), By Value
  • 11.14 India Biologics Market Segmentation - By Product Type, By Application, By End User
  • 11.15 South Korea Biologics Market: Size and Forecast (2015-2025), By Value
  • 11.16 South Korea Biologics Market Segmentation - By Product Type, By Application, By End User

12. Global Biologics Market Dynamics

  • 12.1 Drivers
  • 12.2 Restraints
  • 12.3 Trends

13. Market Attractiveness

  • 13.1 Market Attractiveness Chart of Global Biologics Market - By Product Type, 2025
  • 13.2 Market Attractiveness Chart of Global Biologics Market - By Application, 2025
  • 13.3 Market Attractiveness Chart of Global Biologics Market - By End User, 2025
  • 13.4 Market Attractiveness Chart of Global Biologics Market - By Region, 2025

14. SWOT Analysis

15. Development of Pipeline Products

16. Competitive Landscape

  • 16.1 Market Share Analysis

17. Company Profiles (Business Description, Financial Analysis, Business Strategy)

  • 17.1 Eli Lilly and Company
  • 17.2 Sanofi SA
  • 17.3 Pfizer
  • 17.4 Roche Holding AG
  • 17.5 AbbVie Inc.
  • 17.6 Amgen Inc.
  • 17.7 Merck & Co.
  • 17.8 Novo Nordisk
  • 17.9 Bristol-Myers Squibb Company
  • 17.10 Johnson & Johnson

List of Figures

  • Figure 1: Global Biologics Market Size, By Value, 2015-2025 (USD Billion)
  • Figure 2: Global Non-Communicable Diseases Prevalence (%), 2013-2017
  • Figure 3: Global Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 4: Global Diabetes Mellitus (%), 2013-2017
  • Figure 5: Global Acute Hepatitis B Incidence (%), 2013-2017
  • Figure 6: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
  • Figure 7: Global Biologics Market, By Product Type, 2019, 2025
  • Figure 8: Global Biologics Market- By Product Vaccines, By Value (USD Billion), 2019-2025
  • Figure 9: Global Biologics Market- By Product Monoclonal Ab, By Value (USD Billion), 2019-2025
  • Figure 10: Global Biologics Market- By Product Recombinant Hormones and Proteins, By Value (USD Billion), 2019-2025
  • Figure 11: Global Biologics Market- By Product Cellular and Gene Based, By Value (USD Billion), 2019-2025
  • Figure 12: Global Biologics Market- By Product Others, By Value (USD Billion), 2019-2025
  • Figure 13: Global Biologics Market, By Application, 2019, 2025
  • Figure 14: Global Biologics Market- By Application Cancer, By Value (USD Billion), 2019-2025
  • Figure 15: Global Biologics Market- By Application Rare and Autoimmune Diseases, By Value (USD Billion), 2019-2025
  • Figure 16: Global Biologics Market- By Application Infectious Disease, By Value (USD Billion), 2019-2025
  • Figure 17: Global Biologics Market- By Application Others, By Value (USD Billion), 2019-2025
  • Figure 18: Global Biologics Market, By End User, 2019, 2025
  • Figure 19: Global Biologics Market- By End User Hospitals, By Value (USD Billion), 2019-2025
  • Figure 20: Global Biologics Market- By End User Clinics, By Value (USD Billion), 2019-2025
  • Figure 21: Global Biologics Market- By End User Diagnostic Centres, By Value (USD Billion), 2019-2025
  • Figure 22: Global Biologics Market- By End User Others, By Value (USD Billion), 2019-2025
  • Figure 23: Global Biologics Market, By Region, 2019, 2025
  • Figure 24: North America Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 25: North America Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 26: North America Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 27: North America Diabetes Mellitus (%), 2013-2017
  • Figure 28: North America Respiratory Disorders Incidence (%), 2013-2017
  • Figure 29: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 30: North America Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 31: North America Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 32: North America Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 33: Market Opportunity Chart of North America Biologics Market - By Country, By Value, 2025
  • Figure 34: North America Biologics Market, By Country, 2019, 2025
  • Figure 35: United States Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 36: United States Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 37: United States Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 38: United States Diabetes Mellitus (%), 2013-2017
  • Figure 39: United States Respiratory Disorders Incidence (%), 2013-2017
  • Figure 40: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 41: United States Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 42: United States Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 43: United States Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 44: Canada Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 45: Canada Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 46: Canada Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 47: Canada Diabetes Mellitus (%), 2013-2017
  • Figure 48: Canada Respiratory Disorders Incidence (%), 2013-2017
  • Figure 49: Canada Current health expenditure (% of GDP) 2012-2016
  • Figure 50: Canada Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 51: Canada Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 52: Canada Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 53: Europe Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 54: Europe Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 55: Europe Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 56: Europe Diabetes Mellitus (%), 2013-2017
  • Figure 57: Europe Respiratory Disorders Incidence (%), 2013-2017
  • Figure 58: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 59: Europe Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 60: Europe Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 61: Europe Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 62: Market Opportunity Chart of Europe Biologics Market - By Country, By Value, 2025
  • Figure 63: Europe Biologics Market, By Country, 2019, 2025
  • Figure 64: Germany Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 65: Germany Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 66: Germany Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 67: Germany Diabetes Mellitus (%), 2013-2017
  • Figure 68: Germany Respiratory Disorders Incidence (%), 2013-2017
  • Figure 69: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 70: Germany Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 71: Germany Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 72: Germany Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 73: France Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 74: France Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 75: France Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 76: France Diabetes Mellitus (%), 2013-2017
  • Figure 77: France Respiratory Disorders Incidence (%), 2013-2017
  • Figure 78: France, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 79: France Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 80: France Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 81: France Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 82: United Kingdom Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 83: United Kingdom Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 84: United Kingdom Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 85: United Kingdom Diabetes Mellitus (%), 2013-2017
  • Figure 86: United Kingdom Respiratory Disorders Incidence (%), 2013-2017
  • Figure 87: UK Healthcare Spending, 2018 (USD Per Person)
  • Figure 88: United Kingdom Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 89: United Kingdom Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 90: United Kingdom Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 91: Italy Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 92: Italy Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 93: Italy Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 94: Italy Diabetes Mellitus (%), 2013-2017
  • Figure 95: Italy Respiratory Disorders Incidence (%), 2013-2017
  • Figure 96: Italy, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 97: Italy Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 98: Italy Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 99: Italy Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 100: Asia Pacific Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 101: Asia Pacific Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 102: Asia Pacific Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 103: Asia Pacific Diabetes Mellitus (%), 2013-2017
  • Figure 104: Asia Pacific Respiratory Disorders Incidence (%), 2013-2017
  • Figure 105: Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
  • Figure 106: Asia Pacific Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 107: Asia Pacific Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 108: Asia Pacific Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 109: Market Opportunity Chart of Asia Pacific Biologics Market - By Country, By Value, 2025
  • Figure 110: Asia Pacific Biologics Market, By Country, 2019, 2025
  • Figure 111: China Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 112: China Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 113: China Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 114: China Diabetes Mellitus (%), 2013-2017
  • Figure 115: China Respiratory Disorders Incidence (%), 2013-2017
  • Figure 116: China Healthcare Spending, 2018 (USD Per Person)
  • Figure 117: China Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 118: China Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 119: China Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 120: Japan Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 121: Japan Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 122: Japan Musculoskeletal Disorder Prevalence (%), 2013-2017
  • Figure 123: Japan Diabetes Mellitus (%), 2013-2017
  • Figure 124: Japan Respiratory Disorders Incidence (%), 2013-2017
  • Figure 125: Japan Healthcare Spending, 2018 (USD Per Person)
  • Figure 126: Japan Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 127: Japan Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 128: Japan Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 129: India Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 130: India Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 131: India Rheumatoid Arthritis Prevalence (%), 2013-2017
  • Figure 132: India Diabetes Mellitus (%), 2013-2017
  • Figure 133: India Respiratory Disorders Incidence (%), 2013-2017
  • Figure 134: India Healthcare Spending, 2018 (USD Per Person)
  • Figure 135: India Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 136: India Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 137: India Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 138: South Korea Biologics Market Size, By Value, 2019-2025 (USD Billion)
  • Figure 139: South Korea Non-Communicable Diseases Incidence (%), 2013-2017
  • Figure 140: South Korea Musculoskeletal Prevalence (%), 2013-2017
  • Figure 141: South Korea Diabetes Mellitus (%), 2013-2017
  • Figure 142: South Korea Respiratory Disorders Incidence (%), 2013-2017
  • Figure 143: South Korea Healthcare Spending, 2018 (USD Per Person)
  • Figure 144: South Korea Biologics Market - By Product Segment, By Value, 2015-2025 (USD Billion)
  • Figure 145: South Korea Biologics Market - By Application, By Value, 2015-2025 (USD Billion)
  • Figure 146: South Korea Biologics Market - By End User, By Value, 2015-2025 (USD Billion)
  • Figure 147: Market Attractiveness Chart of Global Biologics Market - By Product Type, 2025
  • Figure 148: Market Attractiveness Chart of Global Biologics Market - By Application, 2025
  • Figure 149: Market Attractiveness Chart of Global Biologics Market - By End User, 2025
  • Figure 150: Market Attractiveness Chart of Global Biologics Market - By Region, 2025
  • Figure 151: Market Share of Leading Global Biologics Manufacturers, 2019 (In %)
  • Figure 152: Eli Lilly Therapeutics, Revenue,2014-2018 (In USD Million)
  • Figure 153: Eli Lilly Revenue, By Region, 2017 (In %)
  • Figure 154: Eli Lilly Revenue, By Region, 2018 (In %)
  • Figure 155: Sanofi SA Revenue, 2014-2018 (In USD Million)
  • Figure 156: Sanofi SA Revenue, By Business Segments, 2017 (In %)
  • Figure 157: Sanofi SA Revenue, By Business Segment, 2018 (In%)
  • Figure 158: Pfizer Revenue, 2014 - 2018 (In USD Billion)
  • Figure 159: Pfizer Sales Revenue, By Region, 2017 (In %)
  • Figure 160: Pfizer Sales Revenue, By Region, 2018 (In %)
  • Figure 161: Pfizer Revenue, By Business Segment, 2017, 2018 (In USD Billion)
  • Figure 162: Pfizer Revenue, By IH Segment, By Region 2018 (In %)
  • Figure 163: Pfizer Revenue, By EH Segment, By Region 2018 (In %)
  • Figure 164: Roche Holding AG, Sales, 2014 - 2018 (In USD Million)
  • Figure 165: Roche Holding AG, Sales, By Segments, 2017 (In %)
  • Figure 166: Roche Holding AG, Sales, By Segments, 2018 (In %)
  • Figure 167: AbbVie Inc., Net Revenue, 2014 - 2018 (In USD Million)
  • Figure 168: AbbVie Inc., Net Sales Revenue, By Region, 2017 (In %)
  • Figure 169: AbbVie Inc., Net Sales Revenue, By Region, 2018 (In %)
  • Figure 170: Amgen Inc. Net Revenue, 2014 - 2018 (In USD Million)
  • Figure 171: Amgen Inc., Net Revenue, By Geographic Region, 2017 (In %)
  • Figure 172: Amgen Inc., Net Revenue, By Geographic Region, 2018 (In %)
  • Figure 173: Merck & Co, Sales, 2014 - 2018 (In USD Million)
  • Figure 174: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2017 (In %)
  • Figure 175: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2018 (In %)
  • Figure 176: Merck & Co, Sales, By Geographic Region, 2017 (In %)
  • Figure 177: Merck & Co, Sales, By Geographic Region, 2018 (In %)
  • Figure 178: Novo Nordisk, Net Sales, 2014 - 2018 (In USD Million)
  • Figure 179: Novo Nordisk A/S, Sales Revenue, By Business Segment , 2017 (In USD Billion)
  • Figure 180: Novo Nordisk A/S, Sales Revenue, ByBusiness Segment, 2018 (In USD Billion)
  • Figure 181: Novo Nordisk A/S , Sales, By Geographic Region, 2017 (In %)
  • Figure 182: Novo Nordisk A/S , Sales, By Geographic Region, 2018 (In %)
  • Figure 183: Bristol-Myers Squibb , Net Revenue, 2014 - 2018 (In USD Billion)
  • Figure 184: Bristol-Myers Squibb, Net Revenue, By Geographic Region, 2017 (In %)
  • Figure 185: Bristol-Myers Squibb, Net Revenue, By Geographic Region, 2018 (In %)
  • Figure 186: Johnson & Johnson, Net Sales, 2014 - 2018 (In USD Million)
  • Figure 187: Johnson & Johnson, Net Sales, By Geographic Region, 2017 (In %)
  • Figure 188: Johnson & Johnson, Net Sales, By Geographic Region, 2018 (In %)
  • Figure 189: Johnson & Johnson, Sales Revenue, By Business Segment , 2017 (In%)
  • Figure 190: Johnson & Johnson, Sales Revenue, ByBusiness Segment, 2018 (In%)